FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Real-time Bid/Ask 04:14:39 2024-05-23 EDT | ||
| 6.25 EUR / 6.27 EUR | -13.77% |
|
| Current month | -24.30% | ||
| 1 month | -42.38% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-22 | 7.26 | +3.42% |
| 24-05-21 | 7.02 | -6.65% |
| 24-05-20 | 7.52 | -8.74% |
| 24-05-17 | 8.24 | +8.14% |
| 24-05-16 | 7.62 | +3.39% |
Delayed Quote Börse Stuttgart
Last update May 22, 2024 at 02:31 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MG01QD |
| ISIN | DE000MG01QD5 |
| Date issued | 2024-03-11 |
| Strike | 1,082 kr |
| Maturity | Unlimited |
| Parity | 2.99 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.46 € |
|---|---|
| Lowest since issue | 6.83 € |
| Spread | 0.02 € |
| Spread % | 0.32% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
923
DKK
Average target price
909.2
DKK
Spread / Average Target
-1.49%
- Stock Market
- Certificates
- Certificat
